Over the coming ten years, the bio-pharma industry's development will be largely driven by technological advancements in new modalities. Investment firms in biotechnology, bio-pharmaceuticals, and life sciences are monitoring this prospect and competing for spots on the most promising platforms [1]. In terms of their manufacturing method or final product structure, bio-pharmaceutical medications made from live cells are typically more sophisticated than the majority of small molecule therapies.
